Pharmacological Management of Chronic Obstructive Lung Disease (COPD). Focus on Mutations - Part 1.
COPD
Classical therapy
SNPs
complexity
eosinophils
personalized-medicine
real-life analysis
systems
approaches.
Journal
Current medicinal chemistry
ISSN: 1875-533X
Titre abrégé: Curr Med Chem
Pays: United Arab Emirates
ID NLM: 9440157
Informations de publication
Date de publication:
2019
2019
Historique:
received:
16
06
2016
revised:
02
08
2017
accepted:
02
04
2018
pubmed:
2
6
2018
medline:
16
7
2019
entrez:
2
6
2018
Statut:
ppublish
Résumé
We report a comprehensive overview of current Chronic Obstructive Lung Disease (COPD) therapies and discuss the development of possible new pharmacological approaches based on "new" knowledge. Specifically, sensitivity/resistance to corticosteroids is evaluated with a special focus on the role of gene mutations in drug response. Critically review the opportunities and the challenges occurring in the treatment of COPD. Findings from "omics" trials should be used to learn more about biological targeted drugs, and to select more specific drugs matching patient's distinctive molecular profile. Specific markers of inflammation such as the percentage of eosinophils are important in determining sensitivity/resistance to corticosteroids. Specific gene variations (Single nucleotide polymorphisms: SNPs) may influence drug sensitivity or resistance. Clinicians working in a real-world need to have a suitable interpretation of molecular results together with a guideline for the treatment and recommendations. Far more translational research is required before new results from omics techniques can be applied in personalized medicine in realworld settings.
Sections du résumé
BACKGROUND
BACKGROUND
We report a comprehensive overview of current Chronic Obstructive Lung Disease (COPD) therapies and discuss the development of possible new pharmacological approaches based on "new" knowledge. Specifically, sensitivity/resistance to corticosteroids is evaluated with a special focus on the role of gene mutations in drug response.
OBJECTIVE
OBJECTIVE
Critically review the opportunities and the challenges occurring in the treatment of COPD.
CONCLUSION
CONCLUSIONS
Findings from "omics" trials should be used to learn more about biological targeted drugs, and to select more specific drugs matching patient's distinctive molecular profile. Specific markers of inflammation such as the percentage of eosinophils are important in determining sensitivity/resistance to corticosteroids. Specific gene variations (Single nucleotide polymorphisms: SNPs) may influence drug sensitivity or resistance. Clinicians working in a real-world need to have a suitable interpretation of molecular results together with a guideline for the treatment and recommendations. Far more translational research is required before new results from omics techniques can be applied in personalized medicine in realworld settings.
Identifiants
pubmed: 29852859
pii: CMC-EPUB-90856
doi: 10.2174/0929867325666180601100235
doi:
Substances chimiques
Adrenal Cortex Hormones
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1721-1733Informations de copyright
Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.